| 何笑冬 江歌丽 刘晓渝 罗杰 李伟 曾晓华.药物联合新辅助化疗（ET）对三阴乳腺癌患者生存状态的
改善及其疗效评价[J].现代生物医学进展英文版,2014,14(7):1346-1349. |
| 药物联合新辅助化疗（ET）对三阴乳腺癌患者生存状态的
改善及其疗效评价 |
| The Improvement of Survival State and Its Curative Effect Evaluation ofDrug Combined with New Adjuvant Chemotherapy (ET)for the Triple Negative Breast Cancer |
| |
| DOI： |
| 中文关键词: 新辅助化疗 表柔比星 多西紫杉醇 三阴乳腺癌 生存状态 疗效评价 |
| 英文关键词: The new adjuvant chemotherapy Epirubicin Docetaxel Triple negative breast cancer Living condition Curative effect
evaluation |
| 基金项目:国家自然科学基金项目（30901919） |
|
| Hits: 946 |
| Download times: 1064 |
| 中文摘要: |
| 目的：观察表柔比星和多西紫杉醇联合新辅助化疗（ET）对三阴乳腺癌患者生存状态的改善及其疗效，评价该化疗方案在三
阴乳腺癌的化疗中加入紫杉类化疗药物的可行性。方法：收集我院2011 年1 月至2011 年12 月收治的300 例乳腺癌患者，将患
者随机分为两组，研究组及对照组，每组各150 例。对照组采用单纯表柔比星，研究组采用新辅助化疗的方案（ET 方案），随访12
个月，统计两组临床疗效并进行评价。结果：研究组完全缓解率（92.00%）明显高于对照组的78.00%，疾病无缓解率（1.33%）及疾
病恶化率（0%）明显低于对照组的14.00%及1.33%，差异具有统计学意义（P<0.01）。随访期间，对照组患者68 例（45.3%）复发或
转移，而研究组患者35 例（23.3%）出现复发或远处转移，两者比较，差异显著（P<0.001）。结论：在三阴乳腺癌的化疗中加入紫杉
类化疗药物是可行的，效果显著。 |
| 英文摘要: |
| Objective:To observe the docetaxel and epirubicin combined with new adjuvant chemotherapy (ET) the improvement
of survival state and its curative effect evaluation, to evaluate the feasible of triple negative breast cancer chemotherapy to join yew
chemotherapeutic drugs.Methods:300 patients with breast cancer admitted in our hospital between January 2011 and December 2011
were collected,and randomly divided into two groups, the treatment group and control group, with 150 cases in each group. Control
group was adopted Epirubicin, the treatment group was used the new adjuvant chemotherapy scheme (ET), the followed up time were 12
months, the clinical curative effect and evaluation in two groups were counted. Results:The complete remission rate in the treatment
group (92.00%)was obviously higher than that in the control group of 78.00%, disease remission rate (1.33%) and disease progression rate
(0%) were significantly lower than the control group of 14.00%and 1.33%, the difference was highly significant (P < 0.01). Follow-up
period, the control group of 68 cases (45.3%) patients were recurrence or metastasis, and the treatment group of 35 patients with
recurrence or distant metastasis (23.3%) appeared, the comparison had significant difference (P < 0.001).Conclusion:Adding Docetaxel
in triple negative breast cancer chemotherapy chemotherapeutic drugs is feasible and effective. |
|
View Full Text
View/Add Comment Download reader |
| Close |
